Retrospective Study to Evaluate Nausea, Vomiting, and Hypersensitivity Reactions in Patients Receiving FOLFOX for Colorectal Cancer at an Infusion Center Not Routinely Administering Prophylactic Dexamethasone by Csovelak, Marissa, PharmD et al.
Lehigh Valley Health Network
LVHN Scholarly Works
Department of Pharmacy
Retrospective Study to Evaluate Nausea, Vomiting,
and Hypersensitivity Reactions in Patients
Receiving FOLFOX for Colorectal Cancer at an
Infusion Center Not Routinely Administering
Prophylactic Dexamethasone
Marissa Csovelak PharmD
Lehigh Valley Health Network, Marissa.Csovelak@lvhn.org
Melissa Kratz RN, MSN, AOCN
Lehigh Valley Health Network, Melissa.Kratz@lvhn.org
Janine Barnaby RPh, BCOP
Lehigh Valley Health Network, Janine.Barnaby@lvhn.org
Follow this and additional works at: https://scholarlyworks.lvhn.org/pharmacy
Part of the Nursing Commons, and the Pharmacy and Pharmaceutical Sciences Commons
This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion in LVHN Scholarly Works by an
authorized administrator. For more information, please contact LibraryServices@lvhn.org.
Published In/Presented At
Csovelak, M., Kratz, M., Barnaby, J. (2015, December 6). Retrospective Study to Evaluate Nausea, Vomiting, and Hypersensitivity
Reactions in Patients Receiving FOLFOX for Colorectal Cancer at an Infusion Center Not Routinely Administering Prophylactic
Dexamethasone. Poster presented at: The 50th Annual ASHP Midyear Clinical Meeting and Exhibition hosted by ASHP, New Orleans,
LA.
Csovelak, M., Kratz, M., Barnaby, J. (2016, May 2-4). Retrospective Study to Evaluate Nausea, Vomiting, and Hypersensitivity Reactions in
Patients Receiving FOLFOX for Colorectal Cancer at an Infusion Center Not Routinely Administering Prophylactic Dexamethasone. Poster
Presented at: The Eastern States Conference for Pharmacy Residents and Preceptors, Hershey, PA.
© 2015 Lehigh Valley Health Network
•		FOLFOX	is	a	first-line	treatment	for	metastatic	colorectal	cancer1
	 	 	 -	 	Oxaliplatin	85	mg/m2	IV	over	2	hours	on	day	1	
	 	 	 -	 	Leucovorin	400	mg/m2	IV	over	2	hours	on	day	1	
	 	 	 -	 	5-Fluorouracil	400	mg/m2	IV	bolus	on	day	1	





	 	 	 -	 	National	Comprehensive	Cancer	Network	(NCCN)	recommends	two	
prophylactic	antiemetics–a	serotonin	(5-HT3)	antagonist	and	a	steroid–for	
patients	receiving	FOLFOX2





	 	 	 -	 	A	histamine-2	(H2)	antagonist,	a	histamine-1	(H1)	antagonist,	and	a	
steroid	may	be	used	as	premedications	to	decrease	the	risk	of	FOLFOX	
hypersensitivity	reactions4
	 	 	 -	 	LVHN	does	not	routinely	premedicate	for	hypersensitivity	reactions
•		Patients	may	receive	reduced	or	delayed	doses	of	FOLFOX	due	to	the	
nausea,	vomiting,	and	hypersensitivity	reactions	associated	with	FOLFOX	 	
	 	 -	 	Dose	intensity	is	related	to	the	overall	survival	of	patients	with	breast	cancer	
who	receive	CMF5
	 	 	 -	 	Dose	intensity	is	related	to	the	overall	survival	of	patients	with	diffuse	large	
B-cell	lymphoma	who	receive	CHOP6	

































				 	 -	 	Estimate	inclusion	of	approximately	150	patients
				 	 -	 	Estimate	approximately	10	to	20%	received	dexamethasone	
•		Inclusion	criteria:
				 	 -	 	Patients	18	years	of	age	or	older
				 	 -	 	Patients	who	received	FOLFOX	at	a	LVHN	infusion	center
•		Exclusion	criteria:
				 	 -	 	Patients	less	than	18	years	of	age
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